<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=EyePoint_Pharmaceuticals%2C_Inc._%28consolidare%29</id>
	<title>EyePoint Pharmaceuticals, Inc. (consolidare) - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=EyePoint_Pharmaceuticals%2C_Inc._%28consolidare%29"/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=EyePoint_Pharmaceuticals,_Inc._(consolidare)&amp;action=history"/>
	<updated>2026-04-30T13:17:33Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=EyePoint_Pharmaceuticals,_Inc._(consolidare)&amp;diff=419225&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei EyePoint Pharmaceuticals, Inc. (consolidare) listata cu simbolul US.EYPTc  ==Descriere companie== EyePoint Pharmaceuticals, Inc. (https://eyepointpharma.com/) is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company's products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technolo...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=EyePoint_Pharmaceuticals,_Inc._(consolidare)&amp;diff=419225&amp;oldid=prev"/>
		<updated>2024-09-18T17:55:16Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei EyePoint Pharmaceuticals, Inc. (consolidare) listata cu simbolul US.EYPTc  ==Descriere companie== EyePoint Pharmaceuticals, Inc. (https://eyepointpharma.com/) is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company&amp;#039;s products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technolo...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei EyePoint Pharmaceuticals, Inc. (consolidare) listata cu simbolul US.EYPTc&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
EyePoint Pharmaceuticals, Inc. (https://eyepointpharma.com/) is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company's products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor. EYP-1901 is in Phase I clinical trial and targeting treatment of wet age-related macular degeneration for additional indications in diabetic retinopathy and retinal vein occlusion. DEXYCU is a single-dose treatment for postoperative inflammation following ocular surgery. YUTIQ50 is a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. It is utilizing its core technology platform, Durasert to deliver drugs and biologics to treat chronic diseases.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.EYPTc&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre EyePoint Pharmaceuticals, Inc. (consolidare) (US.EYPTc)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.EYPTc&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.EYPTc]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>